Prognostic impact of unfavorable cytogenetic abnormalities in multiple myeloma patients treated by Bortezomib (Velcade)

被引：0
|
作者：
Nemec, P.
Greslikova, H.
Zaoralova, R.
Filkova, H.
Kuglik, P.
Oltova, A.
Pour, L.
Adam, Z.
Krivanova, A.
Krejci, M.
Hajek, R.
机构：
[1] Masaryk Univ, Monoclonal Gammopathy & Multiple Myeloma B, Brno, Czech Republic
[2] Masaryk Univ, Fac Sci, Dept Genet & Mol Biol, Brno, Czech Republic
[3] Masaryk Univ, Univ Hosp Brno, Fac Med, Dept Internal Med Hematooncol & Clin Hematol, Brno, Czech Republic
[4] Univ Hosp Brno, Dept Med Genet, Brno, Czech Republic
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：165 / 165
页数：1
相关论文
共 50 条
  • [21] CLINICAL EFFICACY OF VELCADE (BORTEZOMIB) AND DEXAMETHASONE THERAPY IN PATIENTS WITH REFRACTORY OR RELAPSED MULTIPLE MYELOMA
    Ionita, I.
    Cheveresan, M.
    Calamar, D.
    Ionita, C.
    Oros, D.
    Ionita, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 627 - 628
  • [22] PROGNOSTIC IMPLICATIONS OF MULTIPLE CYTOGENETIC HIGH-RISK ABNORMALITIES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
    Binder, M.
    Rajkumar, S. V.
    Ketterling, R. P.
    Dispenzieri, A.
    Lacy, M. Q.
    Gertz, M. A.
    Buadi, F. K.
    Hayman, S. R.
    Hwa, Y. L.
    Zeldenrust, S. R.
    Lust, J. A.
    Russell, S. J.
    Leung, N.
    Kapoor, P.
    Go, R. S.
    Gonsalves, W. I.
    Kyle, R. A.
    Kumar, S. K.
    HAEMATOLOGICA, 2017, 102 : 107 - 107
  • [23] Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma
    Binder, Moritz
    Rajkumar, S. Vincent
    Ketterling, Rhett P.
    Dispenzieri, Angela
    Lacy, Martha Q.
    Gertz, Morie A.
    Buadi, Francis K.
    Hayman, Suzanne R.
    Hwa, Yi L.
    Zeldenrust, Steven R.
    Lust, John A.
    Russell, Stephen J.
    Leung, Nelson
    Kapoor, Prashant
    Go, Ronald S.
    Gonsalves, Wilson I.
    Kyle, Robert A.
    Kumar, Shaji
    BLOOD, 2016, 128 (22)
  • [24] STRUCTURE AND SIGNIFICANCE OF CYTOGENETIC ABNORMALITIES IN PATIENTS WITH MULTIPLE MYELOMA
    Abramova, T., V
    Obukhova, T. N.
    Gribanova, E. O.
    Solovev, M. V.
    Firsova, M. V.
    Votyakova, O. M.
    Kulikov, S. M.
    Chabaeva, Yu A.
    Gal'tseva, I., V
    Mendeleeva, L. P.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2021, 66 (01): : 54 - 67
  • [25] High risk cytogenetic abnormalities in patients with multiple myeloma
    Eugenia Legues, Maria
    Morales, Paulina
    Valenzuela, Mercedes
    Encina, Andrea
    Jose Marti, Maria
    Bascunan, Claudia
    Cornejo, Paulina
    Pena, Camila
    Soledad Undurraga, Maria
    REVISTA MEDICA DE CHILE, 2019, 147 (01) : 61 - 64
  • [26] Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies
    Dimopoulos, M. A.
    Kastritis, E.
    Christoulas, D.
    Migkou, M.
    Gavriatopoulou, M.
    Gkotzamanidou, M.
    Iakovaki, M.
    Matsouka, C.
    Mparmparoussi, D.
    Roussou, M.
    Efstathiou, E.
    Terpos, E.
    LEUKEMIA, 2010, 24 (10) : 1769 - 1778
  • [27] Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies
    M A Dimopoulos
    E Kastritis
    D Christoulas
    M Migkou
    M Gavriatopoulou
    M Gkotzamanidou
    M Iakovaki
    C Matsouka
    D Mparmparoussi
    M Roussou
    E Efstathiou
    E Terpos
    Leukemia, 2010, 24 : 1769 - 1778
  • [28] Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.
    Chang, Hong
    Trieu, Young
    Qi, Xiaoying
    Xu, Wei
    Stewart, Keith
    Reece, Donna
    BLOOD, 2006, 108 (11) : 359B - 359B
  • [29] Prognostic value of selected chromosomal abnormalities in multiple myeloma patients treated by thalidomide
    Zaoralova, R.
    Greslikova, H.
    Filkova, H.
    Nemec, P.
    Kuglik, P.
    Oltova, A.
    Pour, L.
    Adam, Z.
    Krivanova, A.
    Krejci, M.
    Hajek, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 170 - 170
  • [30] Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
    Richard, Shambavi
    Chari, Ajai
    Delimpasi, Sosana
    Simonova, Maryana
    Spicka, Ivan
    Pour, Ludek
    Kriachok, Iryna
    Dimopoulos, Meletios A.
    Pylypenko, Halyna
    Auner, Holger W.
    Leleu, Xavier
    Usenko, Ganna
    Hajek, Roman
    Benjamin, Reuben
    Dolai, Tuphan Kanti
    Sinha, Dinesh Kumar
    Venner, Christopher P.
    Garg, Mamta
    Stevens, Don Ambrose
    Quach, Hang
    Jagannath, Sundar
    Moreau, Phillipe
    Levy, Moshe
    Badros, Ashraf
    Anderson, Larry D., Jr.
    Bahlis, Nizar J.
    Facon, Thierry
    Mateos, Maria Victoria
    Cavo, Michele
    Chang, Hua
    Landesman, Yosef
    Chai, Yi
    Arazy, Melina
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    Grosicki, Sebastian
    Richardson, Paul G.
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (09) : 1120 - 1130
12345